Summary
Before Warfarin therapy is initiated genetic profiling would/should be used to improve patient care(?)
Analysis
I have to agree. When you look at the adverse effects of over- as well as underanticoagulation you will be able to show unnecessary morbity as well as cost. Don't be surprised if the future will be testing for genetic heterogeniety as well as particular molecular profiles prior to initiating therapy.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
